ReviewAmerican journal of translational research2025
Efficacy and safety of pembrolizumab in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis.
Review in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced non-small cell lung cancer (NSCLC) remains a challenging condition with limited treatment options. Pembrolizumab, a programmed death-1 (PD-1) inhibitor, has emerged as a promising therapy, necessitating a comprehensive analysis of its efficacy and safety.
methodsAdhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a thorough search across major electronic databases to compile studies evaluating Pembrolizumab's efficacy and safety in treating advanced NSCLC. Thirteen studies were included based on stringent inclusion and exclusion criteria, focusing on the objective response rate (ORR), disease control rate (DCR), and adverse event incidence. Statistical analyses assessed study heterogeneity and effect sizes, employing fixed or random-effects models as appropriate.
resultsThe meta-analysis revealed an ORR of 0.46 (95% CI: 0.44-0.49) and a DCR of 0.74 (95% CI: 0.69-0.79), indicating significant tumor control and disease management. Sensitivity analyses confirmed the robustness of these findings. The overall incidence of adverse events was reported as 36% (95% CI: 32% to 40%), reflecting a manageable safety profile. Publication bias evaluation showed no significant bias, affirming the reliability of the results.
conclusionsPembrolizumab exhibits substantial efficacy in reducing tumor burden and controlling disease in patients with advanced NSCLC, alongside a consistent safety profile. These findings support its continued use and further research into optimizing treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.